moneyheap
BHVN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Biohaven Ltd. (BHVN) stock moving?
BHVN closed at $15.11 on Nov 10, about 8% below its Oct 29 high of $16.49 and up from a $13.76 low on Nov 6. The stock spiked on 30.5M shares on Oct 22, the day the FDA accepted the Vyglxia resubmission with a 1Q27 goal date, then fell to $13.88 on Oct 23. Volume has since normalized to roughly 1.7M to 3.6M shares a day. The Q3 report on Oct 29 beat the EPS consensus slightly (-$0.73 vs -$0.74), and the stock rallied to $16.49 that day before pulling back. It fell to $13.90 on Nov 5, the day of the Graves' disease Phase 3 enrollment update, then recovered to $15.23 on Nov 9 on 3.6M shares. Recent news flow is constructive: Morgan Stanley (Overweight, PT $21), Canaccord (Buy, PT $32) and Deutsche Bank (Buy, PT $23) all maintained positive ratings, and the average target of about $25 implies roughly 65% upside from the last close. Business development adds non-dilutive cash, with an SK Biopharmaceuticals license providing $400M near-term and an Ono license for BHV-1300 offering $80M upfront received plus up to $20M in milestones. Key risks are the advisory committee date for Vyglxia, which has not been set, the Q1 2027 FDA goal date following a prior action letter, and the Graves' trial still enrolling. Support sits near $13.8 to $13.9 from the Oct 23, Nov 5 and Nov 6 lows, and resistance near $16.1 to $16.5 from the late October highs.
News behind the analysis
- Biohaven Announces Progress Across Its Graves' Disease ProgramBiohaven reported active enrollment in the pivotal Phase 3 trial of BHV-1300 for Graves' disease and presented three scientific posters at the American Thyroid Association meeting. The trial is enrolling at sites in the U.S. and Canada, with more opening in the UK, Japan, Australia and the EU.
- Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EUThe Phase 3 Graves' disease trial of BHV-1300 is enrolling at more than 55 active U.S. and Canadian sites, with more opening in the UK, Japan, Australia and the EU. Three posters were presented at the American Thyroid Association meeting.
- Morgan Stanley Maintains Biohaven at Overweight, Raises Price Target to $21Morgan Stanley reaffirmed its Overweight rating on Biohaven (BHVN) and raised its price target from $19 to $21.
- Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21Morgan Stanley kept its Overweight rating on Biohaven and lifted its price target to $21.
- Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32Canaccord Genuity kept its Buy rating on Biohaven and raised its price target to $32, the highest target among the recent analyst updates.
- Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy RatingDeutsche Bank lowered its 12-month price target on Biohaven to $23 from $26 and kept its Buy rating.
- Biohaven Ltd. Analyst Price Target Adjusted to $25The average 12-month analyst price target for Biohaven was set at $25, a slight decrease from the previous average of $25.17.
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial ResultsBiohaven reported an adjusted loss of $0.73 per share for Q3 2026. The company also reported FDA acceptance of the Vyglxia (troriluzole) resubmission for SCA with a 1Q27 user fee goal date, and a license with SK Biopharmaceuticals providing $400 million in near-term cash.
- Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) EstimateBiohaven's third-quarter adjusted loss of $0.73 per share was slightly better than the $0.74 consensus estimate.
About Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biotech company based in New Haven, Connecticut, developing drugs for neurological, immune and rare diseases as well as cancer. It was spun off when Pfizer bought the original Biohaven in 2022 for its migraine drug Nurtec. Its distinctive programs include opakalim (BHV-7000), an epilepsy drug that activates Kv7 potassium channels, and new 'extracellular degraders' (BHV-1300 for Graves' disease, BHV-1400 for IgA nephropathy) that clear harmful antibodies from the blood.
How it makes money
Biohaven has no meaningful product sales yet and runs at a large loss, roughly $130M+ net loss per quarter in 2026. It pays for research mainly by selling new shares, through financing tied to its drug candidate troriluzole, and through licensing deals. Examples are a 2026 global partnership on its epilepsy drug that shifts development costs to the partner, and a 2026 deal with Ono Pharmaceutical for its IgG degraders in Japan and parts of Asia, which bring upfront and milestone payments. Cash and investments were about $270M as of mid-2026.
What usually moves BHVN
- Clinical trial readouts, especially opakalim in epilepsy
- FDA regulatory actions, such as the 2026 partial clinical hold on opakalim trials
- Data from its antibody-degrader programs (BHV-1300, BHV-1400)
- Licensing and partnership deals
- Cash runway and share dilution from stock sales